Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

54.28 -1.07 (-1.93%)
Official Closing Price Updated: 4:15 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,314,460
Open 55.16
Bid (Size) 54.20 (200)
Ask (Size) 55.50 (200)
Prev. Close 55.35
Today's Range 54.20 - 55.57
52wk Range 34.08 - 56.50
Shares Outstanding 388,132,400
Dividend Yield 1.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory

Performance

YTD
+39.7%
+39.7%
1 Month
+0.8%
+0.8%
3 Month
+19.1%
+19.1%
6 Month
+37.8%
+37.8%
1 Year
+53.3%
+53.3%

More News

Read More
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
Via StockStory
Topics Supply Chain
News headline image
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum ↗
Via Chartmill
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment ↗
Via Chartmill
News headline image
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗
Via The Motley Fool
News headline image
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Royalty Pharma reports first quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unpopular Stocks We’re Skeptical Of
Via StockStory
News headline image
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Declares Second Quarter 2026 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Value Stock for Long-Term Investors and 2 Facing Challenges
Via StockStory
News headline image
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Via StockStory
Topics Energy
News headline image
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
From Royalty Pharma plc
Via GlobeNewswire
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Topics Artificial Intelligence Stocks Supply Chain

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 54.28
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 06/24/26 04:15 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 21.07B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 21B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.